Body Lateralization and Its Effects on Respiratory Drive, Ventilation, and Pulmonary Aerat
The goal of this quasi-experimental study is to investigate how different body positions, performed through Automatic Lateralization Therapy, affect respiratory drive, ventilation, and pulmonary aeration in critically ill adult patients under mechanical ventilation. The main questions this study aims to answer are: * D
| Condition(s) | Intensive Care Units (ICUs) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this quasi-experimental study is to investigate how different body positions, performed through Automatic Lateralization Therapy, affect respiratory drive, ventilation, and pulmonary aeration in critically ill adult patients under mechanical ventilation. The main questions this study aims to answer are: * Does Automatic Lateralization Therapy, modify respiratory drive, as measured by P0.1, estimated Pmus, and sEMG of the diaphragm and parasternal muscles? * Is there an association between respiratory drive, ventilation, and pulmonary aeration measured by Electrical Impedance Tomography (EIT) in different body positions promoted by Automatic Lateralization Therapy ? Does combining Automatic Lateralization Therapy, with Flow Bias improve physiological and functional outcomes comp |
| Who can participate | Inclusion Criteria: * Patients of both sexes will be included; * Aged ≥ 18 years; * BMI 18-35 kg/m²; * Under invasive mechanical ventilation via orotracheal tube for ≥ 24 hours and expected to remain on mechanical ventilatory support for at least 48 hours; * Sedated (Richmond Agitation-Sedation Scale \[RASS\] -1 to -4); * Well adapted to protective ventilation strategies in VCV or PSV modes; * Presenting neural respiratory drive evidenced by a drop in Delta Pocc and/or the presence of assisted cycles; * Hemodynamically stable (mean arterial pressure between 60-120 mmHg, systolic arterial pressure between 90-180 mmHg, diastolic arterial pressure between 60-100 mmHg, and heart rate between 50-150 bpm) with or without vasoactive drugs at the time of data collection (\> 0.1 to 0.3 mcg/kg/min); |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Pernambuco |
| Locations | Recife, Pernamu, Brazil |
| Start date | 2026-01-01 |
| NCT ID | NCT07323472 |
| Official listing | https://clinicaltrials.gov/study/NCT07323472 |